New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C ...

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...

New data from Biogen shows improved motor function in SMA patients using a higher dose of nusinersen, highlighting early treatment benefits. Biogen announced new data from the DEVOTE Part C and ...

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Provided by GlobeNewswire Jun 27, 2025, 2:00:23 PM.

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected ...